Your session is about to expire
← Back to Search
Treatment for Pancreatic Cancer
N/A
Recruiting
Led By Fay Kastrinos, MD
Research Sponsored by Columbia University
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 1 year
Awards & highlights
Summary
The aim of this study is to determine the frequency of the three most common BReast CAncer gene 1 (BRCA1) and BReast CAncer gene 2 (BRCA2) genetic mutations that are commonly found in Ashkenazi Jewish patients with pancreatic cancer. Testing for BRCA1 and BRCA2 mutations in relatives of hereditary pancreatic cancer patients may have a significant impact; allowing for early screening, treatment, and resection of pre-malignant tissue or malignant lesions.
Eligible Conditions
- Pancreatic Cancer
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 1 year
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~1 year
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Frequency of Three BRCA1/2 Mutations in Ashkenazi Jewish Patients
Secondary outcome measures
Frequency of disease modifying mutations
Individual Frequency of Three Mutations
Find a Location
Who is running the clinical trial?
Columbia UniversityLead Sponsor
1,471 Previous Clinical Trials
2,536,250 Total Patients Enrolled
Fay Kastrinos, MDPrincipal InvestigatorColumbia University
Share this study with friends
Copy Link
Messenger